IndicationsStatusPurposePhase
Active Not RecruitingDiagnostic0
clinicaltrials.gov IdentifierTitleDrugs
NCT01875666Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib